BTN2A1-BRAF fusion may be a novel mechanism of resistance to osimertinib in lung adenocarcinoma: a case report

BACKGROUND: Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Osimertinib is a third-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) indicated for NSCLC that effectively targets sensitive epidermal growth factor receptor mutation...

Descripción completa

Detalles Bibliográficos
Autores principales: Kong, Wei-Min, Guo, Yong-Jun, Ma, Jie, Shi, Chao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906054/
https://www.ncbi.nlm.nih.gov/pubmed/36760378
http://dx.doi.org/10.21037/tcr-22-2060

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9906054/
https://www.ncbi.nlm.nih.gov/pubmed/36760378
http://dx.doi.org/10.21037/tcr-22-2060

Ejemplares similares